Physician profile
Tamara L Mccue
NPI 1457339137
$613.28
in general payments reported to CMS, 2019-2025
10 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $26.98 · 2021: $29.85 · 2022: $15.79 · 2023: $70.27 · 2024: $20.04 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $109 · Food and Beverage: $90.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $109.49 |
| Food and Beverage | $90.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $148.21 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $133.56 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $90.31 | 2023-2024 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $74.43 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $59.18 | 2019-2022 | |
| Astellas Pharma US INC | $59.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.18 | 2019 | |
| Lilly USA, LLC | $12.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Mccue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.